Opportunities of Neurometabolic Therapy in the Treatment of Neurological Complications of Diabetes Mellitus
Main Article Content
Abstract
The review describes the effect of neurometabolic therapy with Actovegin on glucose uptake, as well as antioxidant, antihypoxant and other mechanisms of action of the drug. The possibilities of neurometabolic therapy in the treatment of neurological complications of diabetes mellitus are considered. On the basis of analysis of a large number of studies we concluded that Actovegin can be widely used in diabetic polyneuropathy and diabetic encephalopathy.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
References
Аметов A.C. Сахарный диабет. Проблемы и решения. Руководство. — М., 2011. — 680 с.
Верткин А.Л., Скотников А.С., Магомедова А.Ю. и др. Терапия коморбидного больного сахарным диабетом: фокус на гипогликемию // Лечащий врач. — 2013. — № 3. — С. 7-10.
Доказательная эндокринология: Пер. с англ. — 2-е изд. — М., 2008. — 416 с.
Жердьова Н.М. Корекція центральних проявів діабетичної нейропатії // Ліки України. — 2013. — № 1 (167). — С. 76-79.
Кравчун Н.А. Оптимизация медикаментозного лечения диабетической нейропатии: все необходимое доступно // Здоровье Украины. — 2007. — № 15–16. — С. 65.
Локшина А.Б., Захаров В.В. Легкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии // Неврологический журнал. — 2006. — Т. 11. Приложение 1. — С. 57-64.
Моргоева Ф.Э., Аметов A.C, Строков И.А. Диабетическая энцефалопатия и полиневропатия: терапевтические возможности Актовегина // РМЖ. — 2005. — № 6. — С. 302-304.
Нетяженко В.З., Плєнова О.М., Потаскалова В.С.
та ін. Когнітивна функція: вплив цукрового діабету, артеріальної гіпертензії та їх поєднання // Cімейна медицина. — 2013. — № 1. — С. 88-90.
Строков И.А. Результаты плацебо-контролируемого многоцентрового исследования «Актовегин по сравнению с плацебо у пациентов с диабетической полиневропатией» // Атмосфера. Нервные болезни. — 2009. — № 4. — С. 17-21.
Яворская В.А., Егоркина О.В., Машкин О.Н. и др. Клинический опыт применения Актовегина при диабетической полинейропатии // Опыт клинического применения актовегина в эндокринологии. — М., 2005. — С. 27-50.
Brownly M. Biochemistry and molecular cell biology of diabetic complications // Nature. — 2001. — Vol. 414. — P. 813-820.
Jansen W., Beck Е. Лечение диабетической полинейропатии. Контролируемое двойное слепое исследование // Опыт клинического применения актовегина в эндокринологии. — М., 2005. — С. 11-20.
Papanas N., Vinik A., Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? // Nat. Rev. Endocrinol. — 2011. — Vol. 7, № 11. — P. 682-690.
Ziegler D., Movsesyan L., Mankovsky В. et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients // Diabetes Care. — 2009. — Vol. 32, № 8. — P. 1479-1484.
Ziegler D., Rathmann W., Dickhaus T. et al. For the Kora Study Group // Diabetes Care. — 2008. — Vol. 31. — P. 464-469.